Vanda Pharmaceuticals, Inc.

343 articles with Vanda Pharmaceuticals, Inc.

• Vanda Pharmaceuticals to Announce Third Quarter 2020 Financial Results on October 28, 2020

  10/21/2020

   Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2020 on Wednesday, October 28, 2020 , after the market closes.   Vanda will host a conference call at 4:30 PM ET on Wednesday, October 28, 2020 , during w

• Vanda Pharmaceuticals Provides Update on Tradipitant Development Program

  8/31/2020

   Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its development program for tradipitant

• Vanda Pharmaceuticals' Interim Analysis from ODYSSEY Study Shows Tradipitant may Accelerate Clinical Improvement in Patients with COVID-19 Pneumonia

  8/18/2020

  Vanda Pharmaceuticals Inc. reported that interim analysis showed tradipitant may accelerate clinical improvement in SARS-CoV-2 pneumonia in the ODYSSEY study.

• Vanda Pharmaceuticals Reports Second Quarter 2020 Financial Results

  8/5/2020

  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2020.

• FDA Accepts and Grants Priority Review of Vanda's Applications for HETLIOZ® (tasimelteon) in the Treatment of Smith-Magenis Syndrome

  8/3/2020

  Vanda Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has accepted for priority review Vanda's applications for Smith-Magenis Syndrome.

• Vanda Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020

  7/29/2020

  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2020 on Wednesday, August 5, 2020, after the market closes.

• FDA grants authorization for Individual Patient Expanded Access Protocol for the use of tradipitant for gastroparesis

  7/13/2020

  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that the U.S. Food and Drug Administration (FDA) has authorized a single patient in an Individual Patient Expanded Access protocol (VP-VLY-686-3303).

• Vanda Pharmaceuticals Announces Virtual 2020 Stockholder Meeting

  5/26/2020

  Vanda Pharmaceuticals Inc., announced that Vanda will hold its 2020 Annual Meeting of Stockholders in a virtual-only format due to public health concerns related to the COVID-19 pandemic and to protect the health and well-being of its stockholders, directors, employees and the public.

• Vanda Pharmaceuticals CEO's Proposal on Clinical Trial Data Sharing, COVID-19 and Remdesivir

  5/20/2020

  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today released a letter (below) from Mihael H. Polymeropoulos , M.D., President and CEO of Vanda Pharmaceuticals, proposing an approach to Clinical Trial Data Sharing in order to facilitate discovery and clinical utility of COVID-19 therapeutics. Vanda is also involved in the development of

• Vanda Pharmaceuticals Wins Motion To Dismiss False Claims Act Lawsuit

  5/20/2020

  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Federal District Court in Washington D.C. granted Vanda's motion to dismiss a False Claims Act lawsuit filed against the company.

• Vanda Pharmaceuticals Announces Agreement with FDA on Resubmission of the Application for HETLIOZ® for the Treatment of Patients with Smith-Magenis Syndrome

  5/13/2020

   Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that following the completion of a Type A Meeting with the U.S. Food and Drug Administration (FDA) on May 8, 2020 , it has reached agreement with the FDA to resubmit its application for HETLIOZ® (tasimelteon) for the treatment of Smith-Magenis Syndrome (SMS).  As previously

• Vanda Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 6, 2020

  4/29/2020

  Vanda Pharmaceuticals Inc. announced it will release results for the first quarter 2020 on Wednesday, May 6, 2020, after the market closes.

• 

  Clinical Catch-Up: April 13-17

  4/20/2020

  There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.
• 

  Vanda Pharma Launches Clinical Trial and Major Genetic Study of COVID-19

  4/16/2020

  It will test the use of tradipitant for neurogenic inflammation of the lung secondary to SARS-CoV-2 infection.
• 

  Biopharma Update on the Novel Coronavirus: April 16

  4/16/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 16, 2020.

• Vanda Pharmaceuticals Announces Initiation of "CALYPSO" to Study the Role of Genetic Variation in COVID-19 Infections in Collaboration With University of Washington Medicine

  4/15/2020

  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the initiation of the CALYPSO program to study the role that human genetic variations play in SARS-CoV-2 ("COVID-19") infection and disease progression.

• Vanda Pharmaceuticals, Northwell Health Conduct ODYSSEY Trial In Patients With Severe COVID-19 Pneumonia

  4/15/2020

  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and Northwell Health's research arm, The Feinstein Institutes for Medical Research , today announced enrollment of the first patient in Vanda's clinical trial, ODYSSEY VLY-686-3501 (NCT04326426), yesterday at Lenox Hill Hospital in New York City . ODYSSEY is a Phase III double

• Vanda Pharmaceuticals Inc. And The University of Illinois at Chicago Announce Partnership To Identify Novel Antivirals Against COVID-19

  4/8/2020

  Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA) and the University of Illinois at Chicago (UIC) today announced a research partnership focused on the investigation of small molecules with the potential to treat COVID-19.

• Vanda Pharmaceuticals Announces the Initiation of ODYSSEY, an FDA Approved Clinical Study of Tradipitant in Hospitalized Patients with Severe COVID-19 Pneumonia

  4/2/2020

  Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA) today announced the initiation of clinical study, ODYSSEY VLY-686-3501, in hospitalized patients with COVID-19.

• Vanda Pharmaceuticals Announces Participation at March 2020 Investor Conferences

  2/27/2020

  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced that it will participate at the following upcoming investor conferences in March 2020 : The Cowen and Company 40th Annual Health Care Conference in Boston on Tuesday, March 3, 2020 . A corporate presentation is scheduled for 8:40 a.m. Eastern Time